Hydrocarbons, C12-C15, n-alkanes, isoalkanes, <2% aromatics

Sensitisation data (human)

Administrative data

Endpoint:

sensitisation data (humans)

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1988/09/26 - 1988/11/11

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: In accordance with sound scientific principles and performed with good laboratory standards.

Justification for type of information:

A discussion and report on the read across strategy is given as an attachment in IUCLID Section 13.

Cross-reference

Reason / purpose for cross-reference:

read-across: supporting information

Reference

Endpoint:

sensitisation data (humans)

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Study period:

1988/09/26 - 1988/11/11

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: In accordance with sound scientific principles and performed with good laboratory standards.

Justification for type of information:

A discussion and report on the read across strategy is given as an attachment in IUCLID Section 13.

Reason / purpose for cross-reference:

read-across source

Results of examinations:

Phase II: Determination of Phototoxicity and Primary Irritancy
-Results: MRD-88-296 did not elicit any effects which could be construed as a characteristic of a phototoxic propensity or of a primary irritant.
Skin patches exposed to MRD-88-296 displayed no signs of skin irritation. The dermal irritation scores were 0 for all subjects (26 people), on all days of exposure to MRD-88-296. A faint erythema (score of 1) was observed in skin patches exposed to MRD-88-296 and UV light for most subjects, however subjects exposed to only UV light displayed a similar erythema (score of 1).

Phase III - Determination of Photocontact and Contact Allergenic Capabilities
-Results: MRD-88-296 showed no evidence of being a photocontact allergen and no evidence of being either a primary irritant or a contact allergen. No erythema was observed during the rechallenge phase of exposure (score of 0 for all subjects).

Conclusions:

Based on these data and results, MRD-88-296 would not be classified as a dermal irritant or as a dermal sensitizer.

Executive summary:

This data is being read across from the source study that tested Hydrocarbons, C10-C12, isoalkanes,, <2% aromatics based on analogue read across.

This study was conducted to determine the potential of MRD-88-296 to cause dermal irritation and sensitization in humans with or without UV irradiation. Twenty-eight humans were exposed to MRD-88-296. Dermal examinations occurred after exposures (day 1 and day 2) and then at 24h, 48h, and 72h post exposure. Dermal irritation and damage was assessed and scored according to a modified Draize scale. The most severe reaction noted in all experimental paradigms was noted as a "1" or slight erythema. MRD-88-296 did not elicit any effects which could be construed as a characteristic of a phototoxic propensity or of a primary irritant. MRD-88-296 showed no evidence of being a photocontact allergen and no evidence of being either a primary irritant or a contact allergen. Based on these data and results, MRD-88-296 would not be classified as a dermal irritant or as a dermal sensitizer.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1988

Report date:

1988

Materials and methods

Type of sensitisation studied:

skin

Study type:

study with volunteers

Test guideline

Qualifier:

no guideline followed

Principles of method if other than guideline:

human skin patch test

GLP compliance:

yes

Test material

Test material information

Constituent 1

Reference substance name:

Hydrocarbons, C10 – C12, isoalkanes, < 2% aromatics

IUPAC Name:

Hydrocarbons, C10 – C12, isoalkanes, < 2% aromatics

Method

Type of population:

general

Ethical approval:

confirmed, but no further information available

Subjects:

30 participants; 29 participants completed the study.

Clinical history:

A past/present medical history and a brief physical was performed for each individual. Candidates were excluded for any one of the following reasons: systemic illness which might have contra-indicated participation, skin disease, medication which might augment/suppress effects of test material, participation in another sensitization study within the past 10 weeks.

Controls:

Controls were performed

Route of administration:

dermal

Details on study design:

Phase I: Determination of MED (Minimum Erythemogenic Dose - UVB light produced Erythemogenic Effects)
-Design: 5 sites on the back and 5 sites on the arm were exposed to UVB light for either 10,20,30,40, or 50 seconds at 10cm from the exposure site. Sites were examined at 18 and 24 hours.

Phase II: Determination of Phototoxicity and Primary Irritancy
-Design: On each arm, 4 test sites were used with a 5th site serving as a control (no test material applied). Day 1: each testing site had 0.3g of a 50% w/w MRD-88-296 (in U.S.P. Petrolatum) solution applied to it and held in contact with the skin for 24 hours under a semi-occlusive dressing. Day 2: After 24 hours, participants returned and had 0.3 ml of a neat solution of MRD-88-296 (or water if control) applied to the same sites, which was removed after 10 minutes. The right arm was exposed to 15 min UVA and the left arm was not (primary irritant study), both arms were examined for irritation. Participants returned at 24, 48, and 72 hours for an examination for dermal irritation.

Phase III - Determination of Photocontact and Contact Allergenic Capabilities
-Design: On each side of the back, 9 test sites were used for experimental purposes with a 10th site serving as a control (no test material applied). The left side of the back was used to evaluate the irritant and contact allegenic propensities and the evaluation of photocontact allergenic propensities were performed on the right side. 0.3g of a 50% w/w MRD-88-296 solution was used at each experimental site for the evaluation of the propensities.

Results and discussion

Results of examinations:

Phase II: Determination of Phototoxicity and Primary Irritancy
-Results: MRD-88-296 did not elicit any effects which could be construed as a characteristic of a phototoxic propensity or of a primary irritant.
Skin patches exposed to MRD-88-296 displayed no signs of skin irritation. The dermal irritation scores were 0 for all subjects (26 people), on all days of exposure to MRD-88-296. A faint erythema (score of 1) was observed in skin patches exposed to MRD-88-296 and UV light for most subjects, however subjects exposed to only UV light displayed a similar erythema (score of 1).

Phase III - Determination of Photocontact and Contact Allergenic Capabilities
-Results: MRD-88-296 showed no evidence of being a photocontact allergen and no evidence of being either a primary irritant or a contact allergen. No erythema was observed during the rechallenge phase of exposure (score of 0 for all subjects).

Applicant's summary and conclusion

Conclusions:

Based on these data and results, MRD-88-296 would not be classified as a dermal irritant or as a dermal sensitizer.

Executive summary:

This study was conducted to determine the potential of MRD-88-296 to cause dermal irritation and sensitization in humans with or without UV irradiation. Twenty-eight humans were exposed to MRD-88-296. Dermal examinations occurred after exposures (day 1 and day 2) and then at 24h, 48h, and 72h post exposure. Dermal irritation and damage was assessed and scored according to a modified Draize scale. The most severe reaction noted in all experimental paradigms was noted as a "1" or slight erythema. MRD-88-296 did not elicit any effects which could be construed as a characteristic of a phototoxic propensity or of a primary irritant. MRD-88-296 showed no evidence of being a photocontact allergen and no evidence of being either a primary irritant or a contact allergen. Based on these data and results, MRD-88-296 would not be classified as a dermal irritant or as a dermal sensitizer.